Related Experiment Video
Updated: Mar 20, 2026

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
Published on: May 2, 2025
Survival of high-risk pediatric neuroblastoma patients in a developing country
Joseph C Easton1,2, Sergio Gomez3, Peter H Asdahl4
1Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
Insights
Survival for high-risk pediatric neuroblastoma is poor globally. However, survival rates in developing countries like Argentina are dramatically worse, highlighting critical needs for improved treatment and supportive care.
Area of Science:
- Pediatric Oncology
- Global Health
- Cancer Epidemiology
Background:
- Limited data exists on high-risk neuroblastoma patient survival in developing nations.
- Assessing survival disparities is crucial for global pediatric cancer care.
Purpose of the Study:
- To evaluate survival outcomes for high-risk pediatric neuroblastoma patients in La Plata, Argentina.
- To compare survival rates with those reported in developed countries.
Main Methods:
- Retrospective cohort study of 39 high-risk neuroblastoma patients treated between 1999-2015.
- Kaplan-Meier method used to estimate overall survival probabilities.
Main Results:
- Median survival was 1.7 years.
- Five-year overall survival probability was 24%, significantly lower than in developed countries (23-76%).
- High-risk neuroblastoma survival is poor globally, but markedly worse in this developing country cohort.
Conclusions:
- Pediatric neuroblastoma survival is poor in developing countries, underscoring significant global health inequities.
- Improving treatment and supportive care, despite resource limitations, is essential to reduce survival gaps.
Abstract:
Little information is available about survival of high-risk pediatric neuroblastoma patients in developing countries. We aimed to assess survival among high-risk pediatric neuroblastoma patients in La Plata, Argentina. Individuals eligible for our cohort were aged <20 yr when diagnosed with high-risk neuroblastoma and received cancer-directed therapy including stem cell transplantation at Hospital de Niños Sor Maria Ludovica between February 1999 and February 2015. We estimated overall survival probabilities using an extended Kaplan-Meier approach. Our study population comprised 39 high-risk neuroblastoma patients, of whom 39% were aged >4 yr at diagnosis, 54% were male, and 62% had adrenal neuroblastoma. We observed 18 deaths, and the median survival time of our study population was 1.7 yr. The five-yr overall survival probability was 24% (95% CL: 10%, 41%). In contrast, five-yr survival of high-risk neuroblastoma patients ranges between 23% and 76% in developed countries. Survival among high-risk neuroblastoma patients is generally poor regardless of geographic location, but our results illustrate dramatically worse survival for patients in a developing country. We speculate that the observed survival differences could be attenuated or eliminated with improvements in treatment and supportive care, but addressing these issues will require creative solutions because of resource limitations.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Treatment Resistant Cancers

